AlphAIAlphAI — Financial news for AI agents
investing.com$PRQR

ProQR Therapeutics NV earnings beat by €0.01, revenue topped estimates

ProQR Therapeutics NV (PRQR) reported Q3 EPS of €-0.09, beating estimates by €0.01, with revenue of €5.16M, exceeding expectations of €3.78M. The stock is down 34.37% over 3 months and 36.81% over 12 months, closing at €1.26. InvestingPro rates its financial health as 'fair performance'.

Original reporting
investing.com
Published Nov 12, 2026, 4:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 5:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$PRQR
Bullish
medium confidence
Mentioned
$PRQR
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$PRQRBullishLow
01

Why it matters

The modest beat may generate short‑term buying interest but is unlikely to change the longer‑term trajectory given the company's recent price weakness.

02

Market read

Primary relevance is limited to PRQR shareholders; broader market impact is negligible.

03

What to watch

Potential upcoming regulatory or clinical trial milestones could dominate price action more than this earnings beat.

Relevance 6/10Novelty 5/10Timing: after-hours reaction

Background

ProQR Therapeutics NV reported Q3 results that slightly exceeded analyst expectations for both EPS and revenue.

Company-level read

Ticker impact

$PRQRBullishMedium confidence
Context

Q3 earnings beat EPS estimate by €0.01 and revenue beat consensus €5.16M vs €3.78M.

Expected impact

likely modest upside as market prices in the earnings beat

Evidence & confidence

The beat is small and the company is a micro‑cap, so the move is expected to be limited.

Market effects

Sector

Minimal impact on the broader biotech sector; earnings beat is company‑specific.

Regional

Limited to European biotech investors; no broader regional effect.

Global

Low global relevance.

Counterpoint

What could challenge this read

The beat is marginal; investors may remain skeptical given the stock's steep decline over the past year.

Key entities

  • company
    ProQR Therapeutics NV

    NASDAQ‑listed biotech firm reporting Q3 earnings.

Read at source← All news

Related articles

$PRQRMed

ProQR Therapeutics N.V. (PRQR): Financial results for Q2 2026

ProQR Therapeutics N.V. (PRQR) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 ProQR Announces Second Quarter 2026 Operating and Financial Results · First clinical validation of Axiomer™ RNA editing established through NTCP modulation with positive AX-0810 clinical target engagement data; full Phase 1 dataset to be presented at a medical or sci

SEC EDGAR 6-K
$PTHSMed

Pelthos (PTHS) Q3 2026 Earnings Call Transcript

Pelthos (PTHS) reported Q3 2026 net revenue of $15.2M, up 114% YoY, with Zelsuvmi treating 31,000 patients. Formulary coverage expanded to 70% of commercial lives. The company announced a deal with Castle Creek Biosciences, aiming to leverage synergies in dermatology and cell/gene therapy markets. Xepi and Xeglyze launches are planned for 2027.

finance.yahoo.com
$BMNRMedAI 8/10

Bitmine’s ($BMNR) $6.3 Billion Loss Highlights Overall Risks for Strategy ($MSTR) and Other Treasury Firms as MSCI Tightens Rules

Bitmine Immersion Technologies (BMNR) reported a $6.3B net loss for fiscal 2026, driven by $6.23B in unrealized losses on digital-asset holdings, primarily ether. The company held 5.9M ether tokens and 211 bitcoin at year-end. Operating revenue was $125M, with staking contributing 97%. MSCI's updated index rules may impact BMNR and other crypto-focused treasury firms, including Strategy (MSTR).

crowdfundinsider.com